A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Subjects With Glucocorticoid-induced Osteoporosis in Mainland China
Latest Information Update: 03 Jul 2025
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 26 Jun 2025 Planned End Date changed from 27 May 2027 to 24 May 2027.
- 26 Jun 2025 Planned primary completion date changed from 27 May 2027 to 24 May 2027.
- 26 Jun 2025 Status changed from not yet recruiting to recruiting.